November 19th, 2026Podcast: NIH Team Details Path From Ketamine Metabolite Discovery to Phase 2 Trials2R,6R-HNK reproduces ketamine’s rapid antidepressant profile in rodents without dissociation or abuse signals, and is now in four phase 2 trials.Read more
November 18th, 20262027 Plans for OPTI-101 Phase 2b in Major Depressive Disorder and OPTI-201 Phase 3 in PTSDLearn more about the randomized, double-blind phase 2b study of naturally derived psilocybin in MDD, and more. Read more
November 11th, 2026 A Veterans Day Salute: Lessons From 1918 and 2026 for PsychiatristsPsychiatric Times honors those who served with reflections from a World War I diary and new studies on veteran PTSD and suicide risk.Read more
November 10th, 2026First Participant in Phase 3 Study of LPCN 1154 for Postpartum DepressionLipocine has dosed the first participant in BLOOM, their phase 3 study evaluating LPCN 1154 (oral brexanolone) for postpartum depression. Read more
November 6th, 2026Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat DepressionLisa Harding, MD, says ECT, ketamine, TMS, and VNS can work, but evidence on what comes after acute response remains thin.Read more